Midostaurin
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Midostaurin
Midostaurin: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Midostaurin, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 15 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| leukemia, myeloid, acute | licence in another country |
| mastocytosis | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| acute myeloblastic leukemia with maturation |
| acute myeloblastic leukemia without maturation |
| acute myeloid leukemia with cebpa somatic mutations |
| acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) |
| acute myeloid leukemia with minimal differentiation |
| acute myeloid leukemia with npm1 somatic mutations |
| acute myeloid leukemia with t(6;9)(p23;q34) |
| acute myeloid leukemia with t(8;16)(p11;p13) translocation |
| acute myeloid leukemia with t(8;21)(q22;q22) translocation |
| acute myeloid leukemia with t(9;11)(p22;q23) |
| aggressive systemic mastocytosis |
| aleukemic mast cell leukemia |
| inherited acute myeloid leukemia |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 11505M | Rydapt | Capsule 25 mg | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (multikinase inhibitor) |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Haematological parameters (FBC), liver and renal function; please confirm against the PI |
| Handling Protection | Please refer to the PI and local cytotoxic drug handling policy |
Safety Considerations
- Drug Interactions: 100 interactions were recorded in the interaction database; the first 20 reviewed include two Major interactions, with clarithromycin and dolasetron. Most others are Moderate, including antidiabetic agents (acarbose, metformin, pioglitazone, alogliptin, saxagliptin, canagliflozin, dapagliflozin, chlorpropamide, albiglutide, dulaglutide), famotidine, cimetidine, aprepitant, dexamethasone, loperamide, and bowel preparations or laxatives (bisacodyl, picosulfuric acid, polyethylene glycol). The full list should be reviewed before any use.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications, as these were not available in the data compiled for this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.